The Current issue of “The view from here” is concerned with Epigenetics
Drug Discovery Today
MARCH 30, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Epigenetics”.
Drug Discovery Today
MARCH 30, 2022
The topic of this month’s newsletter from Drug Discovery Today is “Epigenetics”.
Drug Channels
APRIL 1, 2022
Today’s guest post comes from Fauzea Hussain, Vice President of Public Policy at McKesson. Fauzea succinctly describes the complicated and contradictory aspects of the Centers for Medicare & Medicaid Services' Final Rule on Best Price, a.k.a. the Medicaid copay accumulator rule. She then outlines how the rule, if implemented, is likely to hurt patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
APRIL 1, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Ireland. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.
Crown Bioscience
MARCH 31, 2022
This post explores the benefits of combining high-content imaging (HCI) and high-content analysis (HCA) with 3D in vitro tumor organoids for drug discovery and validation studies. An increasing number of large in vitro screening studies are showing that novel clinically relevant biomarkers of drug response and important drug effects can be discovered by probing a wider array of cellular parameters combined with dose–response assessments.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Discovery Today
MARCH 28, 2022
Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for AMONDYS+45 Amondys 45 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Sarepta Theraps drug AMONDYS 45 appeared first on DrugPatentWatch - Make Better Decisions.
Sygnature Discovery
MARCH 31, 2022
Take a look at this new paper on drug discovery equipment
Drug Discovery Today
MARCH 28, 2022
Science Minister George Freeman says life sciences have an essential part to play in creating the economy and ecosystem of tomorrow.
Drug Channels
MARCH 28, 2022
Informa Connect’s Medicaid & Government Pricing Congress. Hybrid Event In-Person: May 23-25, 2022, Philadelphia, PA | Virtual: June 1-2, 2022 www.informaconnect.com/medicaid-government-pricing. Don’t miss the Medicaid & Government Pricing Congress , coming up May 23-25, 2022 (in-person in Philadelphia) and June 1-2, 2022 (virtually)! You'll be part of the important discussions surrounding the critical policy updates and approaches to effectively contract, report and comply with state and
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for FIRDAPSE Firdapse is a drug marketed by Catalyst Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Catalyst Pharms drug FIRDAPSE appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 31, 2022
Planned investments of around €2bn over next three years / Shift of resources into strategic pharmaceutical areas by investing in key production sites, manufacturing technologies and supply chain network / Bayer is transforming its pharmaceutical division through enhanced focus on breakthrough innovation as well as through consolidation and modernization of its business operations.
Olympian Clinical Research
MARCH 31, 2022
Anxiety is the most common mental illness in the United States, affecting over 40 million adults every year. With anxiety at an all-time high as we live through a pandemic and an increasingly globalized and technologically advanced world, it can be challenging to understand what type of anxiety you may be experiencing. The most common types of anxiety are social and general anxiety, but how can you tell the difference?
Drug Channels
MARCH 31, 2022
Ah, it’s finally spring in downtown Philadelphia, our home base. (Photographic evidence on your right.) Along with sunshine and fine weather, this vernal equinox has ushered in a crop of new and noteworthy stories: Health inequities in utilization management Insurers compute big white bagging savings The biosimilar boom accelerates The patient upside of manufacturers’ copay support Whoa.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
APRIL 1, 2022
Annual Drug Patent Expirations for CONTRAVE Contrave is a drug marketed by Nalpropion and is included in one NDA. It is available from three suppliers. There are eighteen patents protecting…. The post New patent for Nalpropion drug CONTRAVE appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 29, 2022
With Veeva Development Cloud, Boehringer Ingelheim aims to establish a connected technology landscape for agile collaboration that can accelerate the development of novel medicines Transformation focuses on reducing complexity and developing an innovative, digital culture to better understand and address unmet medical needs. Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless inf
Practical Cheminformatics
MARCH 28, 2022
Clustering Fragment Screening Hits With a Self-Organizing Map (SOM) In a paper, " Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking ", published last year by scientists from UCSF and the Diamond Light Source, the authors reported more than 200 structures of fragments bound to the Nsp3 macrodomain of SARS-CoV-2.
Policy Prescription
APRIL 1, 2022
The U.S. Department of Justice, according to Seeking Alpha , is investigating the sale and distribution of counterfeit drugs in the U.S. that may have amounted to a quarter-billion dollars. The investigation comes about two months after The Wall Street Journal reported on a lawsuit filed by Gilead Sciences alleging a massive breach in the U.S. drug supply chain consisting of $250 million in counterfeit HIV drugs that were sold throughout the U.S. from licensed pharmacies to American patien
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
MARCH 31, 2022
This chart shows the pharmaceutical companies with the most capsule dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most capsule dosed drugs…. The post Which pharmaceutical companies have the most capsule dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 28, 2022
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease.
Molecular Design
MARCH 31, 2022
Enthalpy-driven binding has been presented as a rationale for screening fragments although some have argued that thermodynamic signature is actually a 'red herring' in the context of drug discovery. Binding of a ligand grown from a fragment hit incurs a translational entropy penalty that is similar to that of the original fragment hit and it is therefore it is hardly surprising that synthetic elaboration results in binding that is more driven by entropy.
The Anticancer Fund
APRIL 1, 2022
1 April 2022 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
MARCH 31, 2022
Annual Drug Patent Expirations for NOXAFIL Noxafil is a drug marketed by Merck Sharp Dohme, Schering, and Msd Merck Co and, and is included in four NDAs. It is available…. The post New patent expiration for Schering drug NOXAFIL appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 28, 2022
Efficacy and safety data from the Effisayil™ 1 trial presented at AAD 2022 showed rapid pustular and skin clearance was sustained over 12 weeks in patients with GPP flares treated with spesolimab 1,2,3 Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status 2 Spesolimab also showed clinically significant improvements in GPP flare symptoms, such as pain and fatigue 3.
Eye on FDA
MARCH 30, 2022
Tectonic pandemic plates are shifting respecting the COVID-19 pandemic. For weeks now we have been watching caseloads in the United States broadly fall. It feels as if we are indeed shifting gears. There are other moving parts that are in motion as well. It is a fundamental re-shifting of the landscape. And there are consequences. First, government funding supporting access to vaccination and treatment for COVID has run out and so far, is not replenished.
Drug & Device Law
APRIL 1, 2022
Counsel defending depositions have a decision to make – whether, after opponent’s the direct examination of the witness is complete, whether to “cross-examine” a witness aligned with our own client. Usually, the answer will be “no,” because such questioning usually offers no advantages and could well undermine the witness (who may lose focus under friendly questioning) or provide clues as to the client’s trial strategy.
Drug Patent Watch
MARCH 30, 2022
This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 28, 2022
– Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic –. Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic.
Drug Patent Watch
MARCH 30, 2022
Annual Drug Patent Expirations for KLOXXADO Kloxxado is a drug marketed by Hikma and is included in one NDA. It is available from one supplier. There are two patents protecting…. The post New patent for HIKMA drug KLOXXADO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 29, 2022
This chart shows the patent expirations for cream dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Cream dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.
Let's personalize your content